Loading people...
Johannes Zanzinger is an Investor at the Boehringer Ingelheim Venture Fund, a corporate venture capital firm, based in Cambridge, United States. In this strategic investment role, he specializes in sourcing, evaluating, and managing financial allocations across Seed, Series A, and Series B funding rounds for early-stage biotechnology enterprises. He actively serves as a board director and strategic advisor for select portfolio companies, including the biotechnology startup Rinri Therapeutics, guiding these organizations through complex preclinical and clinical development phases. Prior to transitioning into the venture capital sector, he spent several years working in dedicated research and development roles directly within the broader Boehringer Ingelheim corporate structure. Holding a combined doctorate in veterinary medicine and biomedical research, his current professional focus remains centered on funding novel life sciences startups and advancing breakthrough therapeutics to the commercial market.
Johannes Zanzinger is a key investor at the Boehringer Ingelheim Venture Fund, a corporate venture capital arm dedicated to investing in pioneering life science and health technology companies. In his role, Johannes is instrumental in sourcing, evaluating, and managing investments in early-stage ventures that have the potential to significantly impact human and animal health. His contributions help to drive the fund's mission of supporting innovative science and entrepreneurship.
The Boehringer Ingelheim Venture Fund, and by extension Johannes's investment focus, typically targets areas of high unmet medical need. These often include novel therapeutics across various disease areas such as immunology, cardiometabolic diseases, oncology, central nervous system disorders, and respiratory diseases. The fund also explores cutting-edge health technology platforms that can revolutionize drug discovery, development, or patient care. Johannes Zanzinger's expertise is vital in identifying companies with strong scientific foundations, robust intellectual property, and compelling business models that can thrive in the competitive healthcare landscape.
While specific details of Johannes Zanzinger's career background are not always publicly detailed, professionals in his position typically possess a strong foundation in science, medicine, or finance, often coupled with prior experience in biotechnology, pharmaceuticals, or venture capital. This diverse expertise allows them to critically assess scientific merit, market potential, and operational viability of prospective investments. His work at the Boehringer Ingelheim Venture Fund underscores a commitment to fostering innovation and translating scientific discoveries into tangible health solutions.
Johannes Zanzinger's involvement helps to bridge the gap between scientific research and commercialization, providing crucial capital and strategic guidance to nascent companies. While individual notable investments directly attributed to Johannes Zanzinger are not always publicly disclosed, his efforts contribute to the overall success and impact of the Boehringer Ingelheim Venture Fund's portfolio. The fund's investments aim to create long-term value, not only financially but also in terms of advancing medical science and improving patient outcomes globally. Johannes Zanzinger is an integral part of this mission, working to identify the next generation of healthcare innovators.
Johannes Zanzinger is an investor at the Boehringer Ingelheim Venture Fund, where he focuses on identifying and supporting early-stage life science and health technology companies.
Johannes Zanzinger invests in novel therapeutic and health technology solutions, typically in areas of high unmet medical need, aligning with the Boehringer Ingelheim Venture Fund's strategic focus in life sciences.
Johannes Zanzinger works as an investor at the Boehringer Ingelheim Venture Fund, the corporate venture capital arm of Boehringer Ingelheim.
